T细胞中心的免疫疗法到目前为止已经显示出对雌性激素受体阳性（ER +）乳腺癌有一定的临床益处。尽管占所有乳腺癌的70％，但相对于浸润性导管癌（IDC）和浸润性小叶癌（ILC）的妇女的ER +乳腺癌的免疫生物学知识仍然很少。为了研究这一点，我们对一组未经治疗的IDC（n = 94）和ILC（n = 87）肿瘤进行了表型、转录和功能分析。我们展示了巨噬细胞而不是T细胞是渗入肿瘤床和IDC和ILC之间最具转录多样性的细胞亚群。单元格邻域的分析揭示了在IDC但不是ILC中与较长无疾病生存期相关的巨噬细胞和T细胞之间的相互作用。我们的数据集为进一步探索ER + IDC和ILC中的免疫细胞动态提供了丰富的资源，并突出了巨噬细胞作为ER +乳腺癌的潜在靶点。©2023年。作者，通过Springer Nature America，Inc.独家许可。

T cell-centric immunotherapies have shown modest clinical benefit thus far for estrogen receptor-positive (ER+) breast cancer. Despite accounting for 70% of all breast cancers, relatively little is known about the immunobiology of ER+ breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). To investigate this, we performed phenotypic, transcriptional and functional analyses for a cohort of treatment-naive IDC (n = 94) and ILC (n = 87) tumors. We show that macrophages, and not T cells, are the predominant immune cells infiltrating the tumor bed and the most transcriptionally diverse cell subset between IDC and ILC. Analysis of cellular neighborhoods revealed an interplay between macrophages and T cells associated with longer disease-free survival in IDC but not ILC. Our datasets provide a rich resource for further interrogation into immune cell dynamics in ER+ IDC and ILC and highlight macrophages as a potential target for ER+ breast cancer.© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.